Obesity, polycystic ovarian syndrome and thyroid dysfunction in women with epilepsy

Women with epilepsy (WWE) have an increased risk for several endocrine disorders. Obesity and Polycystic Ovarian Syndrome (PCOS) are common side-effects of anticonvulsant drugs. To study the prevalence of Obesity, PCOS, Thyroid dysfunction in WWE on monotherapy with Carbamazepine (CBZ), Sodium Valpr...

Full description

Saved in:

Bibliographic Details
Published in:	Annals of the Indian Academy of Neurology Vol. 15; no. 2; pp. 101 - 105
Main Authors:	Ayyagari, Mythili, Chitela, Sita Ramu, Kolachana, Venkateswarlu
Format:	Journal Article
Language:	English
Published:	India Medknow Publications and Media Pvt. Ltd 01-04-2012 Medknow Publications & Media Pvt. Ltd Medknow Publications & Media Pvt Ltd Wolters Kluwer Medknow Publications
Subjects:	Age Anticonvulsants Body mass index Carbamazepine Complications and side effects Data processing Diagnosis Drug therapy Drugs Endocrine diseases Epilepsy Hormones Menstruation Obesity Original Phenytoin polycystic ovarian syndrome polycystic ovary syndrome Risk factors Side effects sodium valproate Stein-Leventhal syndrome Thyroid Thyroid diseases Thyroid gland Thyroid-stimulating hormone Ultrasound Women women with epilepsy India Body mass index polycystic ovarian syndrome women with epilepsy thyroid stimulating hormone phenytoin carbamazepine sodium valproate
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Women with epilepsy (WWE) have an increased risk for several endocrine disorders. Obesity and Polycystic Ovarian Syndrome (PCOS) are common side-effects of anticonvulsant drugs. To study the prevalence of Obesity, PCOS, Thyroid dysfunction in WWE on monotherapy with Carbamazepine (CBZ), Sodium Valproate (VAL) and Phenytoin (DPH) MATERIAL AND METHODS: Sixty WWE in the reproductive age group (13 - 45 yr) who are on atleast 6 months of monotherapy with either CBZ (20) or VAL (20) or DPH (20) are subjects of the study. Their Anthropometric data is recorded. They are interviewed and investigated for PCOS and thyroid dysfunction. Twenty healthy women in the reproductive age group served as controls. BMI>25 is taken as cut-off for Obesity. PCOS is defined as menstrual irregularity and/or clinical /biochemical hyperandrogenism with ultrasound evidence of PCO as per the Rotterdam criteria. TSH <0.1 and >4 is taken as evidence of thyroid dysfunction. Women are grouped according to the anticonvulsant drug received and the data analyzed in each group. The mean BMI among VAL and CBZ users is significantly higher than among DPH users (23.3 & 23.4 vs 20.4). There is no significant difference in incidence of PCOS among WWE using either DPH or VAL or CBZ. Elevated TSH>4 is seen more often in WWE on VAL (9/20) compared to CBZ (6/20) and DPH (3/20). WWE on CBZ, VAL and DPH did not differ in mean BMI, Obesity, PCOS compared to healthy controls. As compared to healthy controls, more WWE on drug therapy had significantly elevated TSH (1/20 vs20/60). WWE on VAL and CBZ had significant weight gain compared to DPH users. Despite weight gain, there was no difference in the incidence of PCOS between the users of VAL, CBZ and DPH. As compared to healthy controls, more WWE on drug therapy had significantly elevated TSH, more so in the VAL group.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1
ISSN:	0972-2327 1998-3549
DOI:	10.4103/0972-2327.94992